<DOC>
	<DOCNO>NCT01534897</DOCNO>
	<brief_summary>Radioactive iodine therapy often part standard treatment Papillary Thyroid Carcinoma ( PTC ) patient . However , many patient , tumor develop resistance long respond radioactive iodine therapy ( iodine-refractory ) . Several line evidence suggest block BRAF gene may help re-sensitize tumor radioactive iodine . BRAF protein play central role growth survival cancer cell type PTC . The investigational drug GSK2118436 may work block BRAF protein cancer cell line tumor mutate BRAF gene . In research study , investigator look see GSK2118436 re-sensitize iodine-refractory PTC radioactive iodine therapy . The investigator also look safety add GSK2118436 radioactive iodine therapy .</brief_summary>
	<brief_title>Re-differentiation Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436</brief_title>
	<detailed_description>You take GSK2118436 capsule mouth 28 straight day . If Day 28 whole body radioactive iodine scan demonstrates significant uptake iodine , take GSK2118436 additional 14 day ( Days 29-42 ) . You give drug diary record take GSK2118436 . This diary also contain instruction take GSK2118436 . Prior Day 1 - Optional fine needle aspirate ( pre-treatment ) Day 1 - Vital sign - Routine blood test ( 2 tablespoon ) - Research blood sample Circulating Tumor Cells ( CTCs ) . ( 4 teaspoon blood ) - Optional research blood sample CTCs 4-6 hour first dose GSK2118436 Day 2 : - Optional research blood sample CTCs 4-6 hour first dose GSK2118436 Day 3-5 : Research blood sample CTCs Days 8 15 - Vital sign - Routine blood test ( 2 tablespoon ) - Research blood sample CTCs . ( 4 teaspoon blood ) - Optional fine needle aspirate ( Day 15 ) Low Iodine Diet : You begin low iodine diet Day 15 , preparation Day 23 receive radioactive iodine ( 131I ) . The study team provide instruction diet . The low iodine diet continue whole body scan complete . For participant receive therapeutic dose radioactive iodine Day 37 , low iodine diet continue Day 42 whole body scan complete . Days 21 22 : The drug thyrogen administer injection buttock Days 21 22 preparation whole body radioactive iodine scan Day 28 . Thyrogen use diagnostic tool help determine status cancer approve use thyroid cancer patient . Day 23 : To prepare whole body radioactive iodine scan , ask swallow capsule radioactive iodine absorb remain thyroid cell body . Radioactive iodine approve use thyroid cancer patient . You ask return scan Day 28.You ask sign separate consent radioactive iodine . Days 1-28 : - Optional repeat fine needle aspirate Day 28 - Whole body radioactive iodine scan ass thyroid cancer If Day 28 whole body radioactive iodine scan demonstrates significant uptake iodine , follow test do within 24 hour : - Vital sign - Routine blood test ( 2 tablespoon ) - Research blood sample CTCs . ( 4 teaspoon blood ) - An injection therapeutic dose radioactive iodine administer . If Day 28 whole body radioactive iodine scan demonstrate significant uptake iodine , remove research study . You 3 month follow appointment outline . If Day 28 whole body radioactive iodine scan demonstrates significant uptake iodine , continue treatment GSK2118436 follow study visit : Days 35 36 : The drug thyrogen administer injection buttock Days 35 36 preparation whole body radioactive iodine scan Day 42 . Day 37 : You give therapeutic dose radioactive iodine . You give separate consent form sign radioactive iodine treatment . You ask return whole body radioactive iodine scan Day 42 . Day 39 : - Vital sign - Routine blood test ( 1 tablespoon ) Day 42 : - Whole body radioactive iodine scan - Research blood sample CTCs . ( 4 teaspoon blood ) After final dose study drug : All participant follow visit 3 month stop study drug . You follow test visit : - Routine blood test ( 2 tablespoon ) - Research blood sample CTCs . ( 4 teaspoon blood ) - An assessment tumor CT scan PET/CT scan neck , chest , abdomen pelvis . - Those participant therapeutic dose radioactive iodine Day 37 whole body radioactive iodine scan . - Optional fine needle aspirate</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>Histologically confirm papillary thyroid carcinoma , include variant , tall cell PTC poorly differentiate thyroid carcinoma , metastatic unresectable AND harbor BRAF V600E mutation Evaluable disease , define least one lesion accurately measure least one dimension CT scan ultrasound , present neck Radioiodinerefractory disease Life expectancy &gt; 6 month Able swallow retain oral medication Normal organ marrow function Pregnant breastfeed Previous treatment specific BRAF MEK inhibitor Receiving study agent Known brain metastasis History allergic reaction attribute compound similar chemical biologic composition GSK2118436 , bovine TSH , mannitol iodine Active gastrointestinal disease condition interfere significantly absorption drug History know glucose6phosphate dehyrogenase ( G6PD ) deficiency Corrected QT interval &gt; /= 480 msec ; history acute coronary syndrome ( include unstable angina ) , coronary angioplasty , stenting within past 24 week ; Class II , III , IV heart failure , abnormal cardiac valve morphology ; history know cardiac arrhythmia Taking herbal remedy Subjects significant symptom thyroid cancer , large burden rapidly progressive iodinerefractory PTC need systemic therapy , judge treat physician Uncontrolled current illness include , limited : ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , uncontrolled hypertension psychiatric illness/social situation would limit compliance study requirement History different malignancy unless diseasefree least 5 year deem low risk recurrence HIVpositive combination antiretroviral therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>thyroid cancer</keyword>
	<keyword>Tall cell PTC</keyword>
	<keyword>Poorly differentiate thyroid carcinoma</keyword>
	<keyword>metastatic</keyword>
</DOC>